Stocks Rise Ahead of Inflation Report
Stock futures rose slightly on Friday as investors looked to the end of a losing week and month and awaited key inflation data.Futures for the Dow Jones Industrials popped 197 points, or 0.5%, to 43,494Futures for the S&P 500 index gathered 10.75 points, or 0.2%, to 5,887.Futures for the tech-heavy NASDAQ dropped 10.75 points, or 0.1%, to 21,366.30. The S&P 500 has slid 2.5% week to date, while the Dow has seen more modest losses with a retreat of just 0.4%. Both are down nearly 3% on the month.Traders have been rattled by President Donald Trump’s promise of tariffs and recent economic reports flashing warning signs. A decline of 8.5% in megacap tech titan Nvidia in Thursday’s session the back of earnings threw more cold water on investor sentiment.The personal consumption expenditures price index — the Federal Reserve’s preferred inflation metric — is due for release at 8:30 a.m. ET. Economists polled by Dow Jones expect the measure of price changes for consumers to rise 0.3% from December for an annualized gain of 2.5%. Excluding volatile food and energy prices, so-called core PCE is expected to increase by 0.3% month over month and 2.6% year over year.In Japan, the Nikkei 225 tumbled 2.9%, while in Hong Kong, the Hang Seng collapsed 3.3%. Oil prices fell 89 cents to $69.46 U.S. a barrel. Gold prices dwindled $22.30 to $2,873.600 U.S. an ounce.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


